###begin article-title 0
###xml 52 67 <span type="species:ncbi:10090">transgenic mice</span>
Evolution of somatic mutations in mammary tumors in transgenic mice is influenced by the inherited genotype
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 294 298 294 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FGF </italic>
###xml 351 356 351 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten </italic>
###xml 359 362 359 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P53</italic>
###xml 538 542 538 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 699 708 699 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 10 25 <span type="species:ncbi:10090">transgenic mice</span>
###xml 610 614 <span type="species:ncbi:10090">mice</span>
###xml 699 703 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 708 723 <span type="species:ncbi:10090">transgenic mice</span>
MMTV-Wnt1 transgenic mice develop mammary hyperplasia early in development, followed by the appearance of solitary mammary tumors with a high proportion of cells expressing early lineage markers and many myoepithelial cells. The occurrence of tumors is accelerated in experiments that activate FGF proto-oncogenes or remove the tumor suppressor genes Pten or P53, implying that secondary oncogenic events are required for progression from mammary hyperplasia to carcinoma. It is not known, however, which oncogenic pathways contribute to Wnt1-induced tumorigenesis - further experimental manipulation of these mice is needed. Secondary events also appear to be required for mammary tumorigenesis in MMTV-Neu transgenic mice because the transgene in the tumors usually contains an acquired mutation that activates the Neu protein-tyrosine kinase.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 60 69 60 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1</italic>
###xml 71 84 71 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/p53</italic>
###xml 84 87 84 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 89 98 89 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 135 154 135 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 219 224 219 224 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
###xml 226 231 226 231 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-Ras</italic>
###xml 237 243 237 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-Ras </italic>
###xml 260 269 260 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 60 64 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 71 75 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 89 93 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 98 113 <span type="species:ncbi:10090">transgenic mice</span>
###xml 135 139 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 145 149 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 167 171 <span type="species:ncbi:10090">mice</span>
###xml 260 264 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
cDNA or DNA from the mammary glands and mammary tumors from MMTV-Wnt1, MMTV-Wnt1/p53-/-, MMTV-Neu transgenic mice, and newly generated MMTV-Wnt1/MMTV-Neu bitransgenic mice, was sequenced to seek activating mutations in H-Ras, K-Ras, and N-Ras genes, or in the MMTV-Neu transgene. In addition, tumors from bitransgenic animals were examined to determine the cellular phenotype.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 58 64 58 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 107 117 107 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 197 201 197 201 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 214 223 214 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 280 303 280 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu mice</italic>
###xml 312 316 312 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 319 328 319 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 420 430 420 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 452 456 452 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 513 523 513 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 557 561 557 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P53 </italic>
###xml 107 111 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 117 132 <span type="species:ncbi:10090">transgenic mice</span>
###xml 214 218 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 223 238 <span type="species:ncbi:10090">transgenic mice</span>
###xml 280 284 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 290 294 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 299 303 <span type="species:ncbi:10090">mice</span>
###xml 319 323 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 420 424 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 430 434 <span type="species:ncbi:10090">mice</span>
###xml 513 517 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 523 538 <span type="species:ncbi:10090">transgenic mice</span>
We found activating mutations at codons 12, 13, and 61 of H-Ras in just over half of the mammary tumors in MMTV-Wnt1 transgenic mice, and we confirmed the high frequency of activating mutations of Neu in tumors in MMTV-Neu transgenic mice. Tumors appeared earlier in bitransgenic MMTV-Wnt1/MMTV-Neu mice, but no Ras or MMTV-Neu mutations were found in these tumors, which were phenotypically similar to those arising in MMTV-Wnt1 mice. In addition, no Ras mutations were found in the mammary tumors that arise in MMTV-Wnt1 transgenic mice lacking an intact P53 gene.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 91 97 91 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 104 113 104 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 157 167 157 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 171 180 171 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 104 108 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 157 161 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 171 175 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 180 195 <span type="species:ncbi:10090">transgenic mice</span>
###xml 472 477 <span type="species:ncbi:10090">mouse</span>
Tumorigenic properties of cells undergoing functionally significant secondary mutations in H-Ras or the MMTV-Neu transgene allow selection of those cells in MMTV-Wnt1 and MMTV-Neu transgenic mice, respectively. Alternative sources of oncogenic potential, such as a second transgenic oncogene or deficiency of a tumor suppressor gene, can obviate the selective power of those secondary mutations. These observations are consistent with the notion that somatic evolution of mouse mammary tumors is influenced by the specific nature of the inherited cancer-promoting genotype.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 1070 1071 1070 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1072 1073 1072 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 19 24 <span type="species:ncbi:10090">mouse</span>
###xml 383 408 <span type="species:ncbi:11757">mouse mammary tumor virus</span>
###xml 431 435 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Several transgenic mouse models have been generated in efforts to identify or confirm genes that can participate in breast carcinogenesis and to study the pathogenic process (for review, see [1]). In general, these models have revealed that a wide variety of proto-oncogenes can initiate mammary tumorigenesis when expressed under the control of an appropriate promoter (usually the mouse mammary tumor virus long terminal repeat (MMTV LTR) or the whey acidic protein (WAP) transcriptional control domain). They have also revealed that tumorigenesis is a stochastic process, resulting in the appearance of solitary tumors in one or a few of the 10 mammary glands several months after birth, and that secondary mutational events, inherited deficiencies in tumor suppressor genes, or a combination of transgenes can accelerate the onset of tumor growth. In addition, persistent tumor growth generally requires the continued expression of the initiating oncogene, unless certain secondary mutations have occurred to render the tumor independent of the transgenic oncogene [2-4].
###end p 10
###begin p 11
###xml 239 240 239 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 363 372 363 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB2/Neu</italic>
###xml 378 383 378 383 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
###xml 483 487 483 487 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 489 501 489 498 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#946;-catenin</italic>
###xml 507 512 504 509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-Myc</italic>
###xml 562 563 559 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 575 580 572 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al</italic>
###xml 642 643 639 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 644 645 641 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 912 913 909 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1082 1086 1079 1083 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt </italic>
###xml 1209 1219 1206 1216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB2/Neu </italic>
###xml 1233 1237 1230 1234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 80 95 <span type="species:ncbi:10090">transgenic mice</span>
Despite these generalizations, the characteristics of mammary tumors arising in transgenic mice differ in a fashion characteristic of the initiating oncogene. For example, the expression profiles of tumors reflect the transgenic oncogene [5]; moreover, those tumors induced by genes that activate the Ras signaling pathway (for example, polyoma middle T antigen, ErbB2/Neu, and H-Ras) are more similar to each other than to tumors induced by components of the Wnt signaling pathway (Wnt1, beta-catenin, and c-Myc) with respect both to gene expression patterns ([5], S. Huang et al., in preparation) and to cellular composition and histology [6-9]. In tumors induced by components of the Wnt signaling pathway, a high proportion of cells produce proteins (Sca-1, Keratin 6) associated with early stages of mammary development, whereas few such cells are observed in tumors induced by activators of Ras signaling [9]. In addition, the presence of many tumor cells with myoepithelial features (for example, expression of smooth muscle actin) and other observations suggest that in the Wnt pathway oncogenes transform cells positioned early in the developmental program for mammary tissue, whereas oncogenes like ErbB2/Neu that activate Ras proteins, either transform cells that are more advanced developmentally or drive cells to a more mature epithelial character during oncogenesis.
###end p 11
###begin p 12
###xml 381 391 381 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 449 458 449 458 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Fgf3</italic>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 502 506 502 506 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Fgf </italic>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 516 518 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 554 558 554 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P53 </italic>
###xml 561 566 561 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pten </italic>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 611 635 611 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-c-Myc/MMTV-v-H-Ras </italic>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 695 701 695 701 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-Myc </italic>
###xml 769 775 769 775 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-Myc </italic>
###xml 811 818 811 818 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-Ras2 </italic>
###xml 821 827 821 827 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-Ras </italic>
###xml 834 835 834 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 986 996 986 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ErbB2/Neu </italic>
###xml 1070 1072 1070 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 381 385 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 391 406 <span type="species:ncbi:10090">transgenic mice</span>
###xml 449 453 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 611 615 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 622 626 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 648 652 <span type="species:ncbi:10090">mice</span>
###xml 676 680 <span type="species:ncbi:10090">mice</span>
###xml 701 716 <span type="species:ncbi:10090">transgenic mice</span>
Efforts to understand these complex pathogenic events must take into consideration the secondary oncogenic events that are presumed to be required to convert one or a few of the many mammary cells expressing a transgenic oncogene into a frankly tumorigenic cell. Several findings offer clues to the nature of such secondary events. For example, the appearance of mammary tumors in MMTV-Wnt1 transgenic mice can be accelerated by a second transgene (MMTV-Fgf3, [10]), by proviral insertion mutations in Fgf genes [11-13], and by inherited deficiencies of P53 or Pten [14,15]. Similarly, tumors appear earlier in MMTV-c-Myc/MMTV-v-H-Ras bitransgenic mice than in monotransgenic mice [16], and, in c-Myc transgenic mice, tumors that do not require continued expression of c-Myc usually contain somatically mutated K-Ras2 or N-Ras genes [3]. When tumors occur in animals that inherit a transgene encoding normal ErbB2/Neu protein, the tumors usually exhibit a secondary somatic mutation of ErbB2/Neu that stimulates the protein-tyrosine kinase activity of the gene product [17].
###end p 12
###begin p 13
###xml 131 141 131 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 190 193 190 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras</italic>
###xml 305 313 305 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu</italic>
###xml 357 360 357 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 560 579 560 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 131 135 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 141 156 <span type="species:ncbi:10090">transgenic mice</span>
###xml 305 309 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 560 564 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 570 574 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 592 596 <span type="species:ncbi:10090">mice</span>
In this report, we have attempted to identify additional somatic events that can promote progression to a tumorigenic phenotype in MMTV-Wnt1 transgenic mice by seeking acquired mutations in Ras. In addition, we have asked whether accelerating factors, such as inheritance of a second transgenic oncogene, MMTV-Neu, or deficiency in a tumor suppressor gene, p53, diminishes selection for cells that have acquired potentially oncogenic mutations. In the course of these studies, we were also able to determine that the phenotypic properties of tumors arising in MMTV-Wnt1/MMTV-Neu bitransgenic mice resemble those of tumors induced by Wnt rather than Ras signaling.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice and tissues
###end title 15
###begin p 16
###xml 0 10 0 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 38 47 38 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 83 86 83 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 86 90 86 90 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 38 42 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 110 114 <span type="species:ncbi:10090">mice</span>
###xml 248 252 <span type="species:ncbi:10090">mice</span>
MMTV-Wnt1 (FVB/NJ-Tg [Wnt1] 1 Hev/J), MMTV-Neu (FVB/N-Tg [MMTVNeu] 202 Mul/J), and p53-/- (129-Trp53tm1Tyj/J) mice were purchased from Jackson Labs (Bar Harbor, ME, USA) and maintained or backcrossed for many generations on the FVB background. All mice were maintained in a specific pathogen-free facility on a standard diet.
###end p 16
###begin title 17
RNA, DNA, and protein extraction from tumors
###end title 17
###begin p 18
###xml 904 905 904 905 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 907 908 907 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink">4</sub>
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
Mouse mammary tumors were collected at the time of necropsy or tumor extraction surgery and snap frozen in liquid nitrogen. Frozen tumors were ground in liquid nitrogen and the resulting powder was placed in three tubes containing appropriate buffers. For RNA extraction, about 50 mg of tumor powder was dissolved in Trizol (#15596-018; Invitrogen, Carlsbad, CA, USA), followed by phenol-chloroform extraction and ethanol precipitation. For DNA extraction, about 50 mg of tumor powder was digested overnight with 2 mg/ml Proteinase K (#1 373 200; Roche, Indianapolis, IN, USA) in 20 mM Tris, 200 mM NaCl, 5 mM EDTA, 0.2% SDS, pH 8.5 buffer, followed by phenol-chloroform extraction and ethanol precipitation. For protein extraction, about 50 mg of tumor powder was dissolved in 20 mM Tris, 150 mM NaCl, 1% Triton X, 2 mM EDTA, 1x protease inhibitor cocktail (complete tablets, #1 697 498, Roche), 1 mM Na3VO4, 40 mM NaF, incubated on ice for up to 30 min and cleared by centrifugation.
###end p 18
###begin p 19
###xml 22 32 22 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 76 80 76 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 115 117 115 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 22 26 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Some DNA samples from MMTV-Wnt1 tumors with wild type, heterozygous or null p53 allele (generated by L. Donehower [18]) on a mixed genetic background were a gift from Larry Donehower (Baylor College of Medicine).
###end p 19
###begin title 20
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 8 17 8 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 8 12 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Ras and MMTV-Neu cDNA synthesis
###end title 20
###begin p 21
###xml 249 255 240 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-Ras </italic>
###xml 259 265 250 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-Ras </italic>
###xml 430 436 421 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 243 248 <span type="species:ncbi:10090">mouse</span>
###xml 424 429 <span type="species:ncbi:10090">Mouse</span>
Extracted RNA was copied with gene-specific primers to make cDNA, which was then amplified with the appropriate primers using the SuperScripttrade mark One-Step RT-PCR Kit (#10928-034; Invitrogen) according to manufacturer's instructions. For mouse K-Ras and N-Ras amplification, primer sequences and cycling conditions were kindly provided by Lewis Chodosh and Robert Boxer (University of Pennsylvania School of Medicine). Mouse H-Ras codons 3-99 were amplified either with primers generated based on the sequences provided by Chodosh and Boxer, or with an additional reverse primer spanning exons 2 and 3: HARAS.B2: 5'GATCTGCTCCCTGTACTGATGG3'.
###end p 21
###begin p 22
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 146 150 146 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 142 145 <span type="species:ncbi:10116">rat</span>
MMTV-Neu transgene cDNA was amplified with primers AB2913 and AB1310 [17], which amplify the region corresponding to nucleotides 1492-2117 of rat Neu cDNA.
###end p 22
###begin p 23
Amplification products were purified with QIAquick PCR Purification Kit (#28106; Qiagen, Valencia, CA, USA) according to manufacturer's instructions.
###end p 23
###begin title 24
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
H-Ras DNA synthesis
###end title 24
###begin p 25
###xml 216 222 216 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 308 314 308 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 210 215 <span type="species:ncbi:10090">mouse</span>
###xml 302 307 <span type="species:ncbi:10090">mouse</span>
Tumor DNA was extracted as described above, and extracted DNA was amplified with Taq polymerase (#N808-0152; Roche) in 1 x PCR Buffer (#N808-0006; Roche), 2.5 mM dNTPs in the presence of the following primers: mouse H-Ras exon 1: HRAS.F1A: 5'-CCTTGGCTAAGTGTGCTTC-3', HRAS.B1A: 5'-CCACCTCTGGCAGGTAG-3'; mouse H-Ras exon 2: HRAS.F2A: 5'-GGATTCTCTGGTCTGAGG3-', HRAS.2B2: 5'-GGATATGAGCCAGCTAGC-3'. Amplification was performed for 30 cycles of 15 sec at 94degreesC, 30 sec at 60degreesC and 30 sec at 72degreesC. Amplification products were purified as above.
###end p 25
###begin title 26
Sequencing
###end title 26
###begin p 27
###xml 676 678 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 730 735 730 735 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
###xml 753 760 753 760 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-Ras: </italic>
###xml 776 781 776 781 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-Ras</italic>
###xml 797 800 797 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu</italic>
###xml 724 729 <span type="species:ncbi:10090">mouse</span>
###xml 747 752 <span type="species:ncbi:10090">mouse</span>
###xml 770 775 <span type="species:ncbi:10090">mouse</span>
###xml 793 796 <span type="species:ncbi:10116">rat</span>
All sequencing was carried out by the Memorial Sloan-Kettering Cancer Center (MSKCC) Sequencing Core Facility. Every cDNA was sequenced with both forward and reverse primers used for amplification, and some samples were also sequenced with the nested reverse primer. Sequencing peaks were inspected for overall integrity and legibility. The sample was scored as mutant when heterozygous peaks at positions 12,13, 59, and 61 were at least the same height as the wild type peaks in at least one sequencing direction. Sequences were also downloaded into Vector NTI 5.2.5 (InforMax, Inc., Frederick, MD, USA) program and aligned on the Baylor College of Medicine Search Launcher [19] against the sequences deposited in GenBank (mouse H-Ras: nm008284; mouse K-Ras: xm110615; mouse N-Ras: nm010937, rat Neu: X03362), to detect mutations (or lack of thereof) in the transcripts.
###end p 27
###begin title 28
Immunoblotting and immunohistochemistry
###end title 28
###begin p 29
###xml 690 699 <span type="species:ncbi:3570">Carnation</span>
###xml 761 767 <span type="species:ncbi:9986">rabbit</span>
###xml 925 930 <span type="species:ncbi:10090">mouse</span>
###xml 1074 1080 <span type="species:ncbi:9793">donkey</span>
###xml 1086 1092 <span type="species:ncbi:9986">rabbit</span>
###xml 1167 1170 <span type="species:ncbi:10116">rat</span>
###xml 1176 1181 <span type="species:ncbi:10090">mouse</span>
Proteins were extracted from tumors as described above, and lysates were diluted 1:1 with 2 x sample buffer (#LC2676, Invitrogen) with 10% beta-mercapthoethanol (#M-3148, Sigma, St. Louis, MO, USA), boiled, loaded on Novex SDS/PAGE gels (#EC6075BOX; Invitrogen) and separated by electrophoresis for 1.5 hrs at 125 V and then stained with Coomassie Blue to estimate protein concentrations. Equal amounts of tumor lysates were then reloaded on the 10% SDS/PAGE gels and separated by electrophoresis. Separated proteins were transferred onto nitrocellulose membranes according to the gel manufacturer's instructions. Membranes were incubated for 1 hour with 5% solution of non-fat dried milk (Carnation, Nestle, Solon, OH, USA), followed by 1 hour incubation with rabbit polyclonal antibodies against phospho-ERK, 1:500 dilution, (#9101S; Cell Signaling, Beverly, MA, USA), total ERK, 1:500 dilution, (#9102; Cell Signaling) or mouse monoclonal antibody against gamma-tubulin, 1:1,000 dilution, (GTU88; Sigma), followed by appropriate secondary antibodies conjugated with HRP (donkey-anti-rabbit, 1:10,000, #111-035-144, Jackson Immunochemicals, West Grove, PA, USA; or rat-anti-mouse kappa light chain, 1:2,000, #2067 1323, Zymed, San Francisco, CA, USA).
###end p 29
###begin p 30
###xml 443 446 <span type="species:ncbi:10116">rat</span>
###xml 477 483 <span type="species:ncbi:9986">rabbit</span>
###xml 655 661 <span type="species:ncbi:9986">rabbit</span>
###xml 717 720 <span type="species:ncbi:10116">rat</span>
###xml 818 823 <span type="species:ncbi:10090">mouse</span>
###xml 876 881 <span type="species:ncbi:10090">mouse</span>
###xml 893 899 <span type="species:ncbi:9986">rabbit</span>
Tissues were fixed in 10% buffered formalin (#SF100-4, Fisher, Fair Lawn, NJ, USA) for 16-24 hrs, transferred to 70% ethanol, and shipped to be paraffin-embedded and sectioned at Histoserv (Germantown, MD, USA). Individual sections were deparaffinized, rehydrated and boiled in 1 mM EDTA for antigen retrieval. Slides were then treated with peroxidase, followed by incubation with the appropriate blocking serum from the Vectastain kits (anti-rat-ABC-peroxidase, #PK6104; anti-rabbit-ABC-peroxidase, # PK6101; MOM, # PK2200, Vector Laboratories, Inc., Burlingame, CA, USA) according to manufacturer's instructions. Primary antibodies against phospho-ERK (rabbit polyclonal, #9101S; Cell Signaling), keratin 8 (TROMA, rat polyclonal, Developmental Studies Hybridoma Bank, Iowa City, IA, USA), smooth muscle actin (SMA, mouse monoclonal, #M0851; Dako, Carpinteria, CA, USA), or mouse keratin 6 (rabbit polyclonal, #PRB-169P; Covance, Princeton, NJ, USA) were applied for 1 hr, followed by an incubation with biotin-conjugated appropriate secondary antibody and signal amplification according to Vectastain kit manufacturer's instructions (Vector Laboratories, Inc.). Color was developed with NovaRedtrade mark substrate kit (#SK-4800; Vector Laboratories, Inc.) according to manufacturer's instructions.
###end p 30
###begin title 31
Results
###end title 31
###begin title 32
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 71 81 71 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 71 75 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 81 85 <span type="species:ncbi:10090">mice</span>
Activating mutations in H-Ras occur in about half of mammary tumors in MMTV-Wnt1 mice
###end title 32
###begin p 33
###xml 55 61 55 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-Myc </italic>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 151 157 151 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 213 219 213 219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-Myc </italic>
###xml 230 232 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-Ras </italic>
###xml 253 259 253 259 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-Ras </italic>
###xml 284 289 284 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-Myc</italic>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 390 400 390 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 445 449 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 390 394 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 400 415 <span type="species:ncbi:10090">transgenic mice</span>
Wnt1-induced mammary tumors contain elevated levels of c-Myc RNA and protein, as expected from stimulation of the Wnt signaling pathway [20]. Since an H-Ras transgene can hasten tumorigenesis when combined with a c-Myc transgene [16] and since K-Ras or N-Ras is frequently mutated in c-Myc-induced tumors [3], we decided to look for secondary somatic mutations in mammary tumors arising in MMTV-Wnt1 transgenic mice by sequencing cDNA copies of Ras mRNAs in the tumors. Mutations were scored only if approximately half of the resulting amplified DNA had the same mutation, implying growth selection of an oncogenic cell in which the observed mutation occurred.
###end p 33
###begin p 34
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
###xml 89 94 89 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-Ras</italic>
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-Ras</italic>
###xml 291 296 291 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
###xml 318 324 318 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-Ras </italic>
###xml 327 333 327 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-Ras </italic>
###xml 381 382 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 416 422 416 422 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 541 542 541 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 604 610 604 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 644 650 644 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-Ras </italic>
###xml 654 659 654 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-Ras</italic>
###xml 755 761 755 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 828 838 828 838 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 855 857 855 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 931 933 931 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 957 963 957 963 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 828 832 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 838 853 <span type="species:ncbi:10090">transgenic mice</span>
###xml 914 929 <span type="species:ncbi:10090">transgenic mice</span>
We initially sought activating Ras mutations by sequencing codons 3-99 of H-Ras, 1-98 of N-Ras, and 1-94 of K-Ras. All of the sequences contain codons 12, 13, 59, and 61 - sites of the mutations most commonly associated with oncogenic Ras proteins. We found mutations in codons 12 and 61 of H-Ras, but not in those of N-Ras or K-Ras in cDNA from the first 10 tumor samples (Figure 1). We subsequently focused on the H-Ras cDNA and found activating mutations in codons 12,13, or 61 in 24 of an additional 36 primary mammary carcinomas (Table 1). We then examined 20 tumors without activating mutations in H-Ras for activating point mutations in K-Ras and N-Ras, but failed to find mutations in these two genes. In addition, we were unable to detect mutant H-Ras cDNA made from RNA extracted from hyperplastic mammary glands from MMTV-Wnt1 transgenic mice (n = 6) or from virgin or lactating mammary glands from non-transgenic mice (n = 6), implying that, if H-Ras mutations occurred before the appearance of primary tumors, an insufficient number of cells in the glands harbored the mutations to allow detection, and that selection during tumorigenic growth would be required.
###end p 34
###begin p 35
###xml 90 100 90 100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 145 150 145 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
###xml 362 368 362 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 90 94 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 100 115 <span type="species:ncbi:10090">transgenic mice</span>
###xml 168 172 <span type="species:ncbi:10090">mice</span>
We made a preliminary effort to define the selectable trait conferred on mammary cells in MMTV-Wnt1 transgenic mice by an activating mutation in H-Ras. Tumors in these mice arise after a latency of similar length, have similar growth characteristics, and metastasize to the lungs with similar frequencies regardless of whether they do or do not contain a mutant H-Ras gene (data not shown).
###end p 35
###begin p 36
###xml 74 78 74 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 89 93 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
These findings may simply mean that any requirement for activation of the Ras pathway in Wnt1-induced tumors may be satisfied by some other means, such as other oncogenic mutations; this issue is further addressed in a later section.
###end p 36
###begin p 37
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 402 408 402 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 467 468 467 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
###xml 498 511 498 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-v-H-Ras </italic>
###xml 559 569 559 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 573 583 573 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-c-Myc</italic>
###xml 632 638 632 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 662 664 662 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 769 778 769 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1</italic>
###xml 837 850 837 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-v-H-Ras </italic>
###xml 873 875 873 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1020 1026 1020 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 153 158 <span type="species:ncbi:10090">mouse</span>
###xml 498 502 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 559 563 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 573 577 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 769 773 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 837 841 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
We have also used biochemical methods to look for the consequences of the H-Ras mutations. For example, the oncogenic activity of mutant Ras proteins in mouse cells is dependent on the Raf kinase pathway, which phosphorylates and activates the ERK1/p44 and ERK2/p42 mitogen-activated protein kinases (MAPKs) [21]. We have compared levels of phospho-ERK in Wnt1-induced tumors with mutant and wild type H-Ras genes by protein blotting and immunohistochemistry (Figure 2). While tumors induced by an MMTV-v-H-Ras transgene contained high levels of phospho-ERK, MMTV-Wnt1 and MMTV-c-Myc-induced tumors had lower levels, independent of H-Ras mutation status (Figure 2A). Similarly, there was no difference in phospho-ERK staining patterns in tumor sections from any of the MMTV-Wnt1-induced tumors, although intense staining was observed in MMTV-v-H-Ras induced tumors (Figure 2B). Thus we do not know which of the several signaling pathways affected by Ras may be responsible for growth selection of tumor cells containing H-Ras mutations.
###end p 37
###begin title 38
###xml 40 59 40 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 40 44 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 50 54 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 72 76 <span type="species:ncbi:10090">mice</span>
Mammary tumorigenesis is accelerated in MMTV-Wnt1/MMTV-Neu bitransgenic mice
###end title 38
###begin p 39
###xml 58 60 58 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 61 63 61 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 173 182 173 182 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 186 199 186 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-v-H-Ras </italic>
###xml 216 218 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 266 270 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 376 395 376 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 483 489 483 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 550 556 550 556 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 693 703 693 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 812 821 812 821 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 173 177 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 186 190 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 199 214 <span type="species:ncbi:10090">transgenic mice</span>
###xml 376 380 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 386 390 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 408 412 <span type="species:ncbi:10090">mice</span>
###xml 421 425 <span type="species:ncbi:10090">mice</span>
###xml 652 656 <span type="species:ncbi:10090">mice</span>
###xml 693 697 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 812 816 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Her-2/Neu acts in part through the Ras signaling pathway [22-24], a feature that may account for the remarkable similarity between the phenotypes of mammary tumors found in MMTV-Neu and MMTV-v-H-Ras transgenic mice [25]. These observations suggest that an inherited Neu transgene might mimic the effects of somatic mutation of a Ras gene. If so, tumors might arise earlier in MMTV-Wnt1/MMTV-Neu bitransgenic mice than in mice carrying a single transgene, and any cells that acquired H-Ras mutations would not have a selective growth advantage; hence H-Ras mutations would not be detected in our tests of tumor genotypes. In addition, with bitransgenic mice, we could ask whether a co-existing MMTV-Wnt1 transgene eliminated the selective advantage conferred by an activating mutation in the coding domain of the MMTV-Neu transgene, and we could ask whether the phenotype of tumor cells in resulting tumors resembled the phenotype of tumors induced by components of the Wnt pathway, the Neu/Ras pathway, or both.
###end p 39
###begin p 40
###xml 21 31 21 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 52 61 52 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 161 180 161 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 274 283 274 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 299 309 299 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 333 334 333 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 377 396 377 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 476 486 476 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 493 496 493 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 508 510 508 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 555 564 555 564 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 580 583 580 583 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 595 597 595 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 21 25 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 31 46 <span type="species:ncbi:10090">transgenic mice</span>
###xml 52 56 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 113 116 <span type="species:ncbi:10116">rat</span>
###xml 161 165 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 171 175 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 274 278 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 299 303 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 309 324 <span type="species:ncbi:10090">transgenic mice</span>
###xml 377 381 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 387 391 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 396 400 <span type="species:ncbi:10090">mice</span>
###xml 476 480 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 486 490 <span type="species:ncbi:10090">mice</span>
###xml 555 559 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 573 577 <span type="species:ncbi:10090">mice</span>
Therefore we crossed MMTV-Wnt1 transgenic mice to a MMTV-Neu transgenic line that carries a cDNA encoding normal rat ErbB2/Neu protein [26]. In the bitransgenic MMTV-Wnt1/MMTV-Neu progeny, tumors were detected significantly earlier than in sibling females harboring only an MMTV-Neu transgene or in MMTV-Wnt1 transgenic mice (Figure 3). Over fifty percent (8/14) of the female MMTV-Wnt1/MMTV-Neu mice developed tumors by 12 weeks of age, twice as early as a similar cohort of MMTV-Wnt1 mice (t50 = 25 weeks, n = 44), and almost four times as early as the MMTV-Neu congenic mice (t50 = 39 weeks, n = 26), maintained in the same facility.
###end p 40
###begin p 41
###xml 55 60 55 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1 </italic>
###xml 64 68 64 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 199 203 199 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 280 285 280 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
###xml 346 356 346 356 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 373 374 373 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 409 415 409 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 458 477 458 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 564 569 564 569 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
###xml 616 620 616 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 689 693 689 693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 706 716 706 716 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 719 730 719 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-c-Myc </italic>
###xml 753 754 753 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 757 758 757 758 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 128 133 <span type="species:ncbi:10090">mouse</span>
###xml 346 350 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 458 462 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 468 472 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 706 710 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 719 723 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 730 745 <span type="species:ncbi:10090">transgenic mice</span>
This acceleration of tumor formation demonstrates that Wnt1 and Neu transgenes can cooperate in oncogenic transformation of the mouse mammary gland. To determine whether the presence of an inherited Neu transgene obviated the selective advantage of secondary somatic mutations in H-Ras, observed in many of the mammary tumors induced by a single MMTV-Wnt1 transgene (Table 1), we sequenced DNA amplified from H-Ras RNA obtained from 11 tumors arising in the MMTV-Wnt1/MMTV-Neu bitransgenic animals. None of these samples showed mutations in the first two exons of H-Ras, supporting the notion that the presence of a Neu transgene provided most or all of the growth advantage attributed to Ras mutations in MMTV-Wnt1 or MMTV-c-Myc transgenic mice (Table 1, [3]).
###end p 41
###begin p 42
###xml 31 40 31 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 109 113 109 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 397 401 397 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 460 479 460 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 555 559 555 559 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 638 648 638 648 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 750 754 750 754 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 815 819 815 819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 938 944 938 944 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 947 956 947 956 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1</italic>
###xml 31 35 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 393 396 <span type="species:ncbi:10116">rat</span>
###xml 460 464 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 470 474 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 492 496 <span type="species:ncbi:10090">mice</span>
###xml 638 642 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 947 951 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Mammary tumors reported in the MMTV-Neu monotransgenic line used here have usually acquired mutations in the Neu coding domain of the transgene, enhancing the enzymatic activity of its product; about 70% of these tumors exhibit point mutations, small deletions, or insertions in the extracellular portion of the receptor in or near the cysteine-rich domain encoded by nucleotides 1492-2117 of rat Neu cDNA [17]. However, none of 11 mammary tumors derived from MMTV-Wnt1/MMTV-Neu bitransgenic mice had evidence of mutations in the relevant portions of the Neu transgene. This result has two implications: that the presence of an inherited MMTV-Wnt1 transgene strongly diminishes any selective advantage conferred by secondary somatic mutations in the Neu transgene, and that expression of a wild-type version of the Neu transgene is sufficient to provide the growth advantage that is apparently conferred by secondary somatic mutations of H-Ras in MMTV-Wnt1-induced tumors.
###end p 42
###begin title 43
###xml 14 33 14 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 129 133 129 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 14 18 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 24 28 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
Tumors in the MMTV-Wnt1/MMTV-Neu bitransgenic mice are morphologically similar to Wnt1-induced tumors, despite expression of the Neu transgene
###end title 43
###begin p 44
###xml 0 9 0 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1</italic>
###xml 137 138 137 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 154 163 154 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu-</italic>
###xml 312 313 312 313 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 382 386 382 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 418 421 418 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu</italic>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 643 645 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 678 687 678 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 792 794 792 794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 868 870 868 870 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 0 4 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 154 158 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 678 682 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
MMTV-Wnt1-induced tumors contain multiple mammary cell types, and many cells express early lineage markers, such as Sca-1 and keratin-6 [9]. In contrast, MMTV-Neu-induced mammary tumors are composed nearly exclusively of luminal epithelial cells and have a low proportion of Sca-1- and keratin-6-positive cells [9]. Remarkably, all tumors from bitransgenic mice were similar to the Wnt1-induced tumors, and not to the Neu-induced ones (Figure 4A). We detected multiple cell types within these tumors, including smooth muscle actin-positive myoepithelial cells, keratin-8-positive luminal epithelial cells, and keratin 6-positive cells (Figure 4B, panels a-c). Expression of the MMTV-Neu transgene was observed in the luminal epithelial cells from these tumors by immunohistochemistry (Figure 4B, panel d) and by an RT-PCR assay with transgene-specific primers (Figure 4C).
###end p 44
###begin title 45
###xml 11 17 11 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 84 88 <span type="species:ncbi:10090">mice</span>
Activating H-Ras mutations are not found in Wnt1-induced tumors arising in p53 null mice
###end title 45
###begin p 46
###xml 44 48 44 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 109 119 109 119 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 136 138 136 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 164 171 164 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 201 206 201 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1 </italic>
###xml 237 240 237 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 263 264 263 264 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 310 316 310 316 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 358 368 358 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 383 386 383 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 562 566 562 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 598 602 598 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 716 721 716 721 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
###xml 109 113 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 119 134 <span type="species:ncbi:10090">transgenic mice</span>
###xml 358 362 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
We have previously shown that deficiency of p53 dramatically accelerates the appearance of mammary tumors in MMTV-Wnt1 transgenic mice [14]. More recently, Gunther et al. showed that tumors induced by Wnt1 acquire Wnt1 independence in a p53-deficient background [2]. We therefore asked whether we could detect H-Ras mutations in mammary tumors induced by an MMTV-Wnt1 transgene in a p53-null background; a failure to find such mutations would imply either that p53 is somehow required for such mutations to occur or, more likely, that an inherited deficiency of p53 conferred a growth advantage to Wnt1-expressing mammary cells that would outweigh any selective advantage provided by a secondary somatic mutation in H-Ras.
###end p 46
###begin p 47
###xml 67 77 67 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 89 92 89 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 92 96 92 96 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 125 135 125 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 147 150 147 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 150 154 150 154 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 206 210 206 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 239 243 239 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 308 314 308 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 382 386 382 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 458 464 458 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 507 511 507 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 532 535 532 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 535 539 535 539 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 551 553 551 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 606 610 606 610 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 770 776 770 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 824 830 824 830 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 883 887 883 887 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 915 919 915 919 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 942 946 942 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 957 961 957 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 1017 1021 1017 1021 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 1090 1094 1090 1094 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 67 71 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 125 129 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 154 158 <span type="species:ncbi:10090">mice</span>
To explore this issue, we examined cDNA or DNA from 16 tumors from MMTV-Wnt1 transgenic, p53-/- mice and from 11 tumors from MMTV-Wnt1 transgenic, p53+/- mice, with or without loss of heterozygosity (LOH). Wnt1-induced tumors arising on a p53 heterozygous background, irrespective of the LOH status, contain H-Ras mutations at a frequency (5/11) similar to that described above for Wnt1-induced tumors on a wild type p53 background. Importantly, however, no H-Ras mutations were found in any of the sixteen Wnt1-induced tumors on a p53-/- background (P < 0.05). We conclude that an inherited deficiency of p53 is likely to reduce or eliminate, by an unknown mechanism, any selective growth advantage that might otherwise be contributed by secondary somatic mutations of H-Ras in Wnt1-producing mammary cells. The finding of H-Ras mutations in the small number of tumors with loss of p53 heterozygosity implies that Ras mutation occurs before p53 LOH, since Ras mutations appear not to confer a selective advantage in p53 null cells. However, a larger cohort of tumors undergoing LOH at the p53 locus will be required to establish the conclusion more firmly.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
Most contemporary accounts of oncogenesis assume that multiple mutations affecting tumor suppressor genes and proto-oncogenes collaborate to convert a normal cell into a cancer cell. When these genetic events occur sequentially by somatic mutations during tumor development, it is assumed that the functionally significant mutations confer a selective advantage, such as an augmented rate of growth, protection from apoptosis, or promotion of further mutations, which explains why most if not all cells in a tumor exhibit multiple acquired mutations, consistent with repeated clonal selection.
###end p 49
###begin p 50
###xml 274 280 274 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 323 328 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1-</italic>
###xml 357 358 357 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 397 401 397 401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 445 449 445 449 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 508 512 508 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 610 615 610 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
###xml 665 671 665 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 720 738 720 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu</italic>
###xml 743 746 743 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 758 771 758 771 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/p53</italic>
###xml 771 774 771 774 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 788 789 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 116 120 <span type="species:ncbi:10090">mice</span>
###xml 720 724 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 730 734 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 758 762 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 776 780 <span type="species:ncbi:10090">mice</span>
In this report, we have used several features of recent studies of breast carcinogenesis in genetically manipulated mice to explore the contributions made to a multi-step oncogenic process by a variety of inherited and somatic mutations. We have identified mutations in the H-Ras proto-oncogene as a significant feature of Wnt1-induced tumorigenesis (Table 1), and we have shown that an inherited Neu transgene or an inherited deficiency of the p53 tumor suppressor gene can provide a selective advantage to Wnt1-expressing mammary cells that overrides the selective advantage conferred by somatic mutation of H-Ras. This conclusion is based on our failure to find H-Ras mutations in any tumors arising in bitransgenic (MMTV-Wnt1/MMTV-Neu) or p53-deficient (MMTV-Wnt1/p53-/-) mice (Table 2).
###end p 50
###begin p 51
###xml 45 51 45 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 178 180 178 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 181 183 181 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 328 329 328 329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 330 331 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 332 334 332 334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 335 337 335 337 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 364 370 364 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 383 387 383 387 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 408 412 408 412 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 478 482 478 482 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 508 512 508 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 573 575 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 597 604 597 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo</italic>
###xml 628 634 628 634 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-Ras </italic>
###xml 684 687 684 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 706 709 706 709 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 726 728 726 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 729 731 729 731 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 738 744 738 744 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-Ras </italic>
###xml 787 791 787 791 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 859 861 859 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 862 864 862 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1026 1050 1026 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-TGF-&#945;/MMTV-Neu </italic>
###xml 1064 1072 1060 1068 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu/ p53</italic>
###xml 1072 1073 1068 1069 <italic xmlns:xlink="http://www.w3.org/1999/xlink">R</italic>
###xml 1076 1078 1072 1074 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H </italic>
###xml 1072 1078 1068 1074 <sup xmlns:xlink="http://www.w3.org/1999/xlink"><italic>R</italic>172<italic>H </italic></sup>
###xml 1136 1140 1132 1136 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 1151 1153 1147 1149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1154 1156 1150 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 89 93 <span type="species:ncbi:10090">mice</span>
###xml 279 284 <span type="species:ncbi:10090">mouse</span>
###xml 417 421 <span type="species:ncbi:10090">mice</span>
###xml 720 724 <span type="species:ncbi:10090">mice</span>
###xml 803 808 <span type="species:ncbi:9606">human</span>
###xml 979 984 <span type="species:ncbi:10090">mouse</span>
###xml 1026 1030 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1041 1045 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1059 1063 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1091 1095 <span type="species:ncbi:10090">mice</span>
It is not difficult to reconcile the lack of H-Ras mutations in tumors from bitransgenic mice based on the overlapping signaling pathways in which Neu and Ras participate [22,23,27,28] and on the evidence for similarities in gene expression profiles and cell-type composition of mouse mammary tumors induced by these two genes [5,9,24,25]. However, the absence of H-Ras mutations in Wnt1-induced tumors from p53 null mice is surprising, since it is well known that an activated Ras gene can collaborate with p53 deficiency to promote both transformation of cultured cells [29] and tumor formation in vivo. For example, a mutant K-Ras gene induces lung adenocarcinomas more rapidly in p53-deficient than in p53-wild type mice [30,31], and K-Ras mutations are often accompanied by loss of p53 function in human cancers of the colon, pancreas, and other organs [32-34]. However, effects of inherited mutations on the detection of somatic mutations were previously reported in other mouse models. For example, mammary tumors from MMTV-TGF-alpha/MMTV-Neu and from MMTV-Neu/ p53R172H bitransgenic mice do not contain somatic mutations in the Neu transgene [35,36].
###end p 51
###begin p 52
###xml 57 61 57 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 86 92 86 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 102 103 102 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K</italic>
###xml 108 114 108 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-Ras </italic>
###xml 117 121 117 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 195 202 195 202 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 236 242 236 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-Ras </italic>
###xml 251 256 251 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-Ras</italic>
###xml 268 273 268 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
###xml 313 324 313 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-c-Myc </italic>
###xml 386 397 386 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-c-Myc </italic>
###xml 457 462 457 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
###xml 490 496 490 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-Ras </italic>
###xml 665 669 665 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 278 283 <span type="species:ncbi:10090">mouse</span>
###xml 313 317 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 386 390 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 397 401 <span type="species:ncbi:10090">mice</span>
###xml 906 911 <span type="species:ncbi:10090">mouse</span>
One curious aspect of our findings is the observation of Ras mutations affecting only H-Ras and never K- or N-Ras in Wnt1-induced mammary tumors. This contrasts sharply with the report by D'Cruz et al. [3] of mutations affecting mostly K-Ras and also N-Ras, but never H-Ras, in mouse mammary tumors induced by an MMTV-c-Myc transgene. However, three tumors from the small cohort of the MMTV-c-Myc mice maintained in our lab were found to carry mutations in H-Ras, and one had a mutation in K-Ras (KP, unpublished data). We do not have an explanation for these differences in mutation spectrum and do not know whether they reflect differences in mutational rates at Ras loci (for example, as a consequence of environmental exposures), differences in the selective advantage conferred by different mutant Ras proteins in cells expressing different oncogenes, or differences in the genetic backgrounds of the mouse lines used.
###end p 52
###begin p 53
###xml 71 90 71 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 155 165 155 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1 </italic>
###xml 399 403 399 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Myc </italic>
###xml 432 452 432 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-c-Myc/MMTV-Neu </italic>
###xml 456 481 456 481 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-c-Myc/MMTV-v-Ha-Ras </italic>
###xml 500 501 500 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 539 543 539 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt </italic>
###xml 592 596 592 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ras </italic>
###xml 777 779 777 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 780 782 780 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 71 75 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 81 85 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 155 159 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 165 169 <span type="species:ncbi:10090">mice</span>
###xml 432 436 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 443 447 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 456 460 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 467 471 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 494 498 <span type="species:ncbi:10090">mice</span>
In the course of these experiments we have also found that tumors from MMTV-Wnt1/MMTV-Neu bitransgenic animals were remarkably similar to those induced in MMTV-Wnt1 mice, although they appeared much earlier than tumors in monotransgenic animals, indicating cooperative effect of the two transgenes. The dominant effect of Wnt1 expression in these tumors closely resembles the dominant effect of the Myc transgene in tumors from the MMTV-c-Myc/MMTV-Neu and MMTV-c-Myc/MMTV-v-Ha-Ras bitransgenic mice [6]. This observation suggests that the Wnt signaling pathway has a dominant effect over the Ras signaling pathway in transformation of mammary epithelial cells. This might be related to the recently described effects of Wnts on stem cell maintenance during normal development [37-40]. Dominance of the Wnt phenotype in this cross might also be explained by a difference in time and level of transgene expression in the mammary tissue.
###end p 53
###begin title 54
Conclusions
###end title 54
###begin p 55
###xml 44 49 <span type="species:ncbi:10090">mouse</span>
Selection of somatic oncogenic mutations in mouse mammary tumors depends on the nature of inherited factors: transgenic oncogenes and loss of function mutations in tumor suppressor genes.
###end p 55
###begin title 56
Competing interests
###end title 56
###begin p 57
None declared.
###end p 57
###begin title 58
Authors' contributions
###end title 58
###begin p 59
###xml 96 115 96 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 144 160 144 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt/p53-/- </italic>
###xml 96 100 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 106 110 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 144 148 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
KP planned, analyzed, and presented the experiments described in this paper. KP carried out the MMTV-Wnt1/MMTV-Neu cross and YL carried out the MMTV-Wnt/p53-/- cross. YL helped to analyze the data and contributed to editing the manuscript. HV helped to plan and oversee the experiments and contributed to the writing and editing of the manuscript.
###end p 59
###begin title 60
Pre-publication history
###end title 60
###begin p 61
The pre-publication history for this paper can be accessed here:
###end p 61
###begin p 62

###end p 62
###begin title 63
Acknowledgements
###end title 63
###begin p 64
###xml 277 283 277 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">K-Ras </italic>
###xml 287 293 287 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N-Ras </italic>
###xml 94 99 <span type="species:ncbi:10090">mouse</span>
###xml 271 276 <span type="species:ncbi:10090">mouse</span>
The authors thank Jennifer Doherty, Mary Barrett, and Daisy Chen for expert technical help in mouse colony maintenance and assistance in tumor cDNA preparation and IHC staining. Some DNA samples were a gift from Larry Donehower (Baylor College of Medicine, TX, USA). For mouse K-Ras and N-Ras amplification, primer sequences and cycling conditions were kindly provided by Lewis Chodosh and Robert Boxer (University of Pennsylvania School of Medicine).
###end p 64
###begin article-title 65
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
###xml 27 32 <span type="species:ncbi:9606">human</span>
Transgenic mouse models of human breast cancer
###end article-title 65
###begin article-title 66
Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis
###end article-title 66
###begin article-title 67
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations
###end article-title 67
###begin article-title 68
###xml 59 74 <span type="species:ncbi:10090">transgenic mice</span>
Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis
###end article-title 68
###begin article-title 69
###xml 66 71 <span type="species:ncbi:9606">human</span>
Initiating oncogenic event determines gene-expression patterns of human breast cancer models
###end article-title 69
###begin article-title 70
###xml 11 16 <span type="species:ncbi:10090">mouse</span>
Transgenic mouse models of mammary tumorigenesis
###end article-title 70
###begin article-title 71
###xml 20 24 <span type="species:ncbi:10090">mice</span>
Transgenic oncogene mice. Tumor phenotype predicts genotype
###end article-title 71
###begin article-title 72
###xml 50 65 <span type="species:ncbi:10090">transgenic mice</span>
Comparative pathology of mammary tumorigenesis in transgenic mice
###end article-title 72
###begin article-title 73
Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells
###end article-title 73
###begin article-title 74
###xml 108 123 <span type="species:ncbi:10090">transgenic mice</span>
Transgenes expressing the Wnt-1 and int-2 proto-oncogenes cooperate during mammary carcinogenesis in doubly transgenic mice
###end article-title 74
###begin article-title 75
###xml 80 95 <span type="species:ncbi:10090">transgenic mice</span>
Preferential activation of Fgf8 by proviral insertion in mammary tumors of Wnt1 transgenic mice
###end article-title 75
###begin article-title 76
###xml 0 25 <span type="species:ncbi:11757">Mouse mammary tumor virus</span>
###xml 80 95 <span type="species:ncbi:10090">transgenic mice</span>
Mouse mammary tumor virus infection accelerates mammary carcinogenesis in Wnt-1 transgenic mice by insertional activation of int-2/Fgf-3 and hst/Fgf-4
###end article-title 76
###begin article-title 77
###xml 79 85 <span type="species:ncbi:10090">murine</span>
Fgf-8, activated by proviral insertion, cooperates with the Wnt-1 transgene in murine mammary tumorigenesis
###end article-title 77
###begin article-title 78
###xml 61 76 <span type="species:ncbi:10090">transgenic mice</span>
Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability
###end article-title 78
###begin article-title 79
###xml 54 58 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 65 80 <span type="species:ncbi:10090">transgenic mice</span>
Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice
###end article-title 79
###begin article-title 80
###xml 16 20 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 34 38 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 54 69 <span type="species:ncbi:10090">transgenic mice</span>
Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo
###end article-title 80
###begin article-title 81
Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors
###end article-title 81
###begin article-title 82
###xml 0 4 <span type="species:ncbi:10090">Mice</span>
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
###end article-title 82
###begin article-title 83
BCM Search Launcher: Multiple Alignments
###end article-title 83
###begin article-title 84
Identification of c-MYC as a target of the APC pathway
###end article-title 84
###begin article-title 85
###xml 45 50 <span type="species:ncbi:9606">human</span>
###xml 58 63 <span type="species:ncbi:10090">mouse</span>
Distinct requirements for Ras oncogenesis in human versus mouse cells
###end article-title 85
###begin article-title 86
###xml 114 119 <span type="species:ncbi:9606">human</span>
Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2)-induced mammary tumorigenesis: implications for human breast cancer
###end article-title 86
###begin article-title 87
Multiple ErbB-2/Neu Phosphorylation Sites Mediate Transformation through Distinct Effector Proteins
###end article-title 87
###begin article-title 88
###xml 44 49 <span type="species:ncbi:9606">human</span>
Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2
###end article-title 88
###begin article-title 89
Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors
###end article-title 89
###begin article-title 90
###xml 65 80 <span type="species:ncbi:10090">transgenic mice</span>
Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease
###end article-title 90
###begin article-title 91
Oncogenic Ras/Her-2 mediate hyperproliferation of polarized epithelial cells in 3D cultures and rapid tumor growth via the PI3K pathway
###end article-title 91
###begin article-title 92
Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors
###end article-title 92
###begin article-title 93
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells
###end article-title 93
###begin article-title 94
###xml 75 79 <span type="species:ncbi:10090">mice</span>
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
###end article-title 94
###begin article-title 95
Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes
###end article-title 95
###begin article-title 96
Molecular genetics of small cell lung carcinoma
###end article-title 96
###begin article-title 97
Molecular epidemiology of pancreatic cancer
###end article-title 97
###begin article-title 98
Genetic alterations in the adenoma - carcinoma sequence
###end article-title 98
###begin article-title 99
###xml 67 82 <span type="species:ncbi:10090">transgenic mice</span>
neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice
###end article-title 99
###begin article-title 100
###xml 124 139 <span type="species:ncbi:10090">transgenic mice</span>
Synergistic interaction of the Neu proto-oncogene product and transforming growth factor alpha in the mammary epithelium of transgenic mice
###end article-title 100
###begin article-title 101
Links between signal transduction, transcription and adhesion in epithelial bud development
###end article-title 101
###begin article-title 102
A role for Wnt signalling in self-renewal of haematopoietic stem cells
###end article-title 102
###begin article-title 103
Wnt proteins are lipid-modified and can act as stem cell growth factors
###end article-title 103
###begin article-title 104
Live and let die in the intestinal epithelium
###end article-title 104
###begin title 105
Figures and Tables
###end title 105
###begin p 106
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 81 87 81 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 127 137 127 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 127 131 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 137 141 <span type="species:ncbi:10090">mice</span>
Mutations in the H-Ras gene. Representative examples of somatic mutations in the H-Ras cDNA from primary mammary tumors of the MMTV-Wnt1 mice. Sequence chromatograms of codons 12, 13, and 61 are shown as they appear in the forward and reverse sequencing directions. Mutant peaks are indicated by arrows. The nucleotide and amino acid alterations are indicated on the right.
###end p 106
###begin p 107
###xml 23 33 23 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 57 63 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 74 78 74 78 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 113 126 113 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-v-H-Ras </italic>
###xml 149 159 149 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 192 198 192 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 416 420 412 416 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 452 465 448 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-v-H-Ras </italic>
###xml 479 489 475 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 513 519 509 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 555 561 551 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 23 27 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 113 117 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 126 131 <span type="species:ncbi:10090">mouse</span>
###xml 149 153 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 452 456 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 465 470 <span type="species:ncbi:10090">mouse</span>
###xml 479 483 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 489 493 <span type="species:ncbi:10090">mice</span>
ERK phosphorylation in MMTV-Wnt1 tumors with and without H-Ras mutations. (A) Protein lysates from tumors from a MMTV-v-H-Ras mouse (first lane) and MMTV-Wnt1 mice with and without activating H-Ras mutations were subjected to electrophoresis in 10% polyacrylamide gels, transferred to a nitrocellulose membrane and then exposed to antibodies against phospho-ERK, total ERK and gamma-tubulin as described in Methods. (B) Primary tumor sections from (a) MMTV-v-H-Ras mouse and (b) MMTV-Wnt1 mice without activating H-Ras mutations and (c,d) with activating H-Ras mutations were incubated with antibodies against phospho-ERK as described in Methods.
###end p 107
###begin p 108
###xml 41 50 41 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 54 73 54 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 89 99 89 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 120 129 120 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 133 152 133 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 186 196 186 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 205 214 205 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 282 292 282 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 364 366 364 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 408 418 408 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 41 45 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 54 58 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 64 68 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 89 93 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 120 124 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 133 137 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 143 147 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 159 163 <span type="species:ncbi:10090">mice</span>
###xml 186 190 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 205 209 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 221 225 <span type="species:ncbi:10090">mice</span>
###xml 282 286 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 408 412 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Kaplan-Meiyer plot of tumor incidence in MMTV-Neu and MMTV-Wnt1/MMTV-Neu siblings and in MMTV-Wnt1 historical controls. MMTV-Neu and MMTV-Wnt1/MMTV-Neu female mice generated by crossing MMTV-Wnt1 male and MMTV-Neu female mice were inspected weekly for mammary tumors. The number of MMTV-Wnt1 females generated in this cross was too low to include in the analysis (n = 4). The rate of appearance of tumors in MMTV-Wnt1 females in a previously studied cohort maintained under the same conditions is presented instead.
###end p 108
###begin p 109
###xml 12 31 12 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 75 79 75 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Wnt1</italic>
###xml 122 126 122 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Neu </italic>
###xml 137 141 137 141 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(A) </bold>
###xml 188 196 188 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu</italic>
###xml 202 211 202 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1</italic>
###xml 224 243 224 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 310 319 310 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 410 420 410 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 443 447 443 447 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(B) </bold>
###xml 840 844 840 844 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(C) </bold>
###xml 952 961 952 961 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Neu </italic>
###xml 1002 1012 1002 1012 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 1042 1061 1042 1061 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 12 16 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 22 26 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
###xml 188 192 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 202 206 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 224 228 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 234 238 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 243 247 <span type="species:ncbi:10090">mice</span>
###xml 310 314 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 319 324 <span type="species:ncbi:10090">mouse</span>
###xml 410 414 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 437 441 <span type="species:ncbi:10090">mice</span>
###xml 529 534 <span type="species:ncbi:10090">mouse</span>
###xml 910 913 <span type="species:ncbi:10116">rat</span>
###xml 952 956 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 961 966 <span type="species:ncbi:10090">mouse</span>
###xml 1002 1006 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1012 1017 <span type="species:ncbi:10090">mouse</span>
###xml 1042 1046 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1052 1056 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 1061 1066 <span type="species:ncbi:10090">mouse</span>
Tumors from MMTV-Wnt1/MMTV-Neu mice exhibit morphologic characteristics of Wnt1-induced tumors, despite expression of the Neu transgene. (A) Histological appearance of the tumors from (a) MMTV-Neu, (b) MMTV-Wnt1, and (c, d) MMTV-Wnt1/MMTV-Neu mice. Note solid morphology and scant stroma in the tumor from the MMTV-Neu mouse, in contrast with branched ductular architecture and dense stroma of the tumors from MMTV-Wnt1 and bitransgenic mice. (B) Immunohistochemistry on the consecutive sections of the tumor from a bitransgenic mouse with the following mammary lineage markers: (a) anti-smooth muscle actin (SMA), (b) anti-keratin 8 (TROMA), (c) anti-keratin 6, and (d) anti-Her2/Neu marker Ab3, was performed as described in Methods. The Her2/Neu marker is expressed in a subpopulation of cells similar to the one positive for keratin 8. (C) Detection of Neu RNA in mammary glands and tumors. RT-PCR for the rat Neu on the total RNA samples from the MMTV-Neu mouse mammary gland (MG) and tumor (MT), MMTV-Wnt1 mouse mammary tumor (MT), and MMTV-Wnt1/MMTV-Neu mouse mammary tumor (MT) and gland (MG).
###end p 109
###begin p 110
###xml 22 28 22 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 41 51 41 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1 </italic>
###xml 41 45 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Frequency and type of H-Ras mutations in MMTV-Wnt1 tumors
###end p 110
###begin p 111
###xml 52 57 52 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
Primary tumor cDNA was amplified and sequenced with H-Ras-specific primers at least once in each direction as described in Methods. Products containing mutant peaks equal to or greater in height than the wild type peaks in at least one sequencing direction were scored as mutation-positive. Mutations in codons 12,13, 59, and 61 were scored as activating mutations.
###end p 111
###begin p 112
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras </italic>
###xml 32 45 32 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/p53</italic>
###xml 45 48 45 48 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/-</sup>
###xml 50 63 50 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/p53</italic>
###xml 63 66 63 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/-</sup>
###xml 72 91 72 91 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/MMTV-Neu </italic>
###xml 32 36 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 50 54 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 72 76 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 82 86 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Frequency of H-Ras mutations in MMTV-Wnt1/p53+/-, MMTV-Wnt1/p53-/-, and MMTV-Wnt1/MMTV-Neu tumors
###end p 112
###begin p 113
###xml 24 37 24 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/p53</italic>
###xml 37 41 37 41 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 61 74 61 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MMTV-Wnt1/p53</italic>
###xml 74 78 74 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-/- </sup>
###xml 114 118 114 118 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+/- </sup>
###xml 161 166 161 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">H-Ras</italic>
###xml 24 28 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 61 65 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
###xml 101 105 <span type="species:ncbi:11757?0.9246724890829694">MMTV</span>
Primary tumor cDNAs (11 MMTV-Wnt1/p53-/- samples) or DNAs (5 MMTV-Wnt1/p53-/- samples and all of the MMTV-Wnt1/p53+/- samples) were amplified and sequenced with H-Ras-specific primers at least once in each direction, as described in Methods. Mutations were scored by the same criteria described in Table 1.
###end p 113

